Table 2.
20 ARRIVE checklists | Fully reported n/N(% reported) | Partially reported n/N (% reported) | Not reported n/N(% reported) | |
---|---|---|---|---|
1 | Title | 22/22 (100) | 0/22 (0) | 0/22 (0) |
2 | Abstract | 12/22 (54.5) | 10/22 (45.5) | 0/22 (0) |
3 | Background | 0/22 (0) | 21/22 (95.5) | 1/22 (4.5) |
4 | Objectives | 21/22 (95.5) | 0/22 (0) | 1/22 (4.5) |
5 | Ethical statement | 16/22 (72.7) | 0/22 (0) | 6/22 (27.3) |
6 | Study design | 1/22 (4.5) | 20/22 (91) | 1/22 (4.5) |
7 | Experimental procedure | 0/22 (0) | 22/22 (100) | 0/22 (0) |
8 | Experimental animals | 2/22 (9.1) | 19/22 (86.4) | 1/22 (4.5) |
9 | Housing and husbandry | 0/22 (0) | 4/22 (18.2) | 18/22 (81.8) |
10 | Sample size | 0/22 (0) | 0/22 (0) | 22/22 (100) |
11 | Allocating animals | 0/22 (0) | 10/22 (45.5) | 12/22 (54.5) |
12 | Experimental outcomes | 22/22 (100) | 0/22 (0) | 0/22 (0) |
13 | Statistical methods | 0/22 (0) | 20/22 (90.9) | 2/22 (9.1) |
14 | Baseline data | 10/22 (45.5) | 0/22 (0) | 12/22 (54.5) |
15 | Numbers analyzed | 2/22 (9.1) | 1/22 (4.5) | 19/22 (86.4) |
16 | Outcomes and estimation | 7/22 (31.8) | 14/22 (63.7) | 1/22 (4.5) |
17 | Adverse events | 6/22 (27.3) | 0/22 (0) | 16/22 (72.7) |
17a | Details of adverse events | 0/22 (0) | 0/22 (0) | 22/22 (100) |
18 | Interpretation/scientific implications | 0/22 (0) | 22/22 (100) | 0/22 (0) |
19 | Generalizability/translation | 0/22 (0) | 0/22 (0) | 22/22 (100) |
20 | Funding | 11/22 (50) | 0/22 (0) | 11/22 (50) |
N, total number of papers where the item was applicable; n, total number of papers reporting the item.